Andrew Tsai
Andrew Tsai is a financial analyst at Jefferies, specializing in the biotechnology sector. He is noted for his optimistic outlook on the potential success of azetukalner, predicting that it could become a leading epilepsy treatment and generate over a billion dollars in annual sales.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Jefferies analyst Andrew Tsai said in a recent note that the drug has already produced one of the most compelling pivotal datasets in focal epilepsy.
8